Overview

Study of INBRX-101 Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
Phase 2 study to compare INBRX-101 to plasma derived A1PI therapy in adults with AATD emphysema
Phase:
Phase 2
Details
Lead Sponsor:
Inhibrx, Inc.
Treatments:
Alpha 1-Antitrypsin